<DOC>
<DOCID> eng-NG-31-106441-6425952 </DOCID>
<DOCTYPE SOURCE="usenet"> USENET TEXT </DOCTYPE>
<DATETIME> 2007-03-28T11:40:00 </DATETIME>
<BODY>
<HEADLINE>
A recurrent mutation in PALB2 in Finnish cancer families
</HEADLINE>
<TEXT>
<POST>
<POSTER> "Athar Aziz" &lt;ptcgr...@gmail.com&gt; </POSTER>
<POSTDATE> 2007-03-28T11:40:00 </POSTDATE>
*Nature* *446*, 316-319 (15 March 2007) | doi:10.1038/nature05609; Received
5 December 2006; Accepted 19 January 2007; Published online 7 February 2007;
Corrected&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;15
March 2007
A recurrent mutation in *PALB2* in Finnish cancer families

Hannele Erkko1&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;
,12&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Bing Xia5&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;
,12&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Jenni Nikkilä1&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Johanna Schleutker6&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Kirsi Syrjäkoski6&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Arto Mannermaa7&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Anne Kallioniemi6&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Katri Pylkäs1&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Sanna-Maria Karppinen1&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Katrin Rapakko1&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Alexander Miron5&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Qing Sheng5&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Guilan Li5&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Henna Mattila6&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Daphne W. Bell8&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;
,13&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Daniel A. Haber8&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Mervi Grip2&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Mervi Reiman1&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Arja Jukkola-Vuorinen3&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Aki Mustonen1&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Juha Kere9&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;
,10&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Lauri A. Aaltonen9&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Veli-Matti Kosma7&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Vesa Kataja11&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Ylermi Soini4&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
Ronny I. Drapkin5&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;,
David M. Livingston5&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;and
Robert Winqvist
1&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;

1. Department of Clinical Genetics,
2. Department of Surgery,
3. Department of Oncology,
4. Department of Pathology, University of Oulu and Oulu University
Hospital, FIN-90029 OYS, Finland
5. Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney
Street, Boston, Massachusetts 02115, USA
6. Laboratory of Cancer Genetics, Institute of Medical Technology,
FIN-33520 University of Tampere and Tampere University Hospital, Finland
7. Institute of Clinical Medicine, Pathology and Forensic Medicine,
University of Kuopio and Department of Clinical Pathology, Kuopio University
Hospital, FIN-70211 Kuopio, Finland
8. Cancer Center and Department of Pathology, Massachusetts General
Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA
9. Department of Medical Genetics, University of Helsinki and
Biomedicum Helsinki, FIN-00014 HY, Finland
10. Department of Biosciences and Nutrition, and Clinical Research
Centre, Karolinska Institutet, SE-17177 Huddinge, Sweden
11. Institute of Clinical Medicine, Oncology, University of Kuopio and
Department of Oncology, Kuopio University Hospital, FIN-70211 Kuopio,
Finland
12. These authors contributed equally to the work.
13. Present address: National Human Genome Research Institute/NIH,
Bethesda, Maryland 20892, USA.

Correspondence to: David M.
Livingston5&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;Robert
Winqvist1&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;Correspondence
and requests for materials should be addressed to
R.W. (Email: robert.winqv ... @oulu.fi) or D.M.L. (Email:
david_livings ... @dfci.harvard.edu).

*BRCA1*, *BRCA2* and other known susceptibility genes account for less than
half of the detectable hereditary predisposition to breast cancer1,
&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;2,
&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;
3&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;.
Other relevant genes therefore remain to be discovered. Recently a new
BRCA2-binding protein, PALB2, was
identified4&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;.
The BRCA2–PALB2 interaction is crucial for certain key BRCA2 DNA damage
response functions as well as its tumour suppression
activity4&lt; http://www.nature.com.gate2.inist.fr/nature/journal/v446/n7133/full/n... &gt;.
Here we show, by screening for *PALB2* mutations in Finland that a
frameshift mutation, c.1592delT, is present at significantly elevated
frequency in familial breast cancer cases compared with ancestry-matched
population controls. The truncated PALB2 protein caused by this mutation
retained little BRCA2-binding capacity and was deficient in homologous
recombination and crosslink repair. Further screening of c.1592delT in
unselected breast cancer individuals revealed a roughly fourfold enrichment
of this mutation in patients compared with controls. Most of the
mutation-positive unselected cases had a familial pattern of disease
development. In addition, one multigenerational prostate cancer family that
segregated the c.1592delT truncation allele was observed. These results
indicate that *PALB2* is a breast cancer susceptibility gene that, in a
suitably mutant form, may also contribute to familial prostate cancer
development.
</POST>
</TEXT>
</BODY>
</DOC>
